abrdn Life Sciences Investors
About this Fund
abrdn Life Sciences Investors is a leading mutual fund company specializing in the art of asset management, providing a diverse range of investment solutions to cater to the unique needs of its discerning clientele. By leveraging its expertise in wealth management, the company offers a portfolio of meticulously crafted mutual funds that span across various asset classes, including equity, debt, and hybrid funds, thereby enabling investors to navigate the complexities of the financial landscape with confidence. The company's investment approach is centered around a deep understanding of the life sciences sector, with a focus on identifying high-growth opportunities that can potentially yield substantial returns over the long term. abrdn Life Sciences Investors' equity funds, for instance, are designed to capitalize on the growth potential of companies operating in the biotechnology, pharmaceutical, and medical devices industries, while its debt funds provide a stable source of income with relatively lower risk. The company also offers hybrid funds that combine the benefits of equity and debt investments, providing a balanced portfolio that can help mitigate risk while generating returns. For investors seeking a disciplined and systematic approach to investing, abrdn Life Sciences Investors offers a systematic investment plan, or SIP, which allows them to invest a fixed amount of money at regular intervals, thereby reducing the impact of market volatility. The company's investor-centric approach, coupled with its commitment to transparency and accountability, has earned it the trust of its clients, who value its ability to deliver tailored investment solutions that meet their unique financial objectives. With a strong focus on research and analysis, abrdn Life Sciences Investors' team of experienced investment professionals works tirelessly to identify emerging trends and opportunities in the life sciences sector, enabling the company to stay ahead of the curve and make informed investment decisions. By combining its expertise in asset management with a deep understanding of the life sciences industry, abrdn Life Sciences Investors has established itself as a trusted partner for investors seeking to navigate the complexities of the financial markets and achieve their long-term wealth management goals. The company's commitment to excellence, integrity, and client satisfaction has fostered a culture of trust and loyalty among its clients, who appreciate its dedication to delivering exceptional investment results and unparalleled customer service. As a result, abrdn Life Sciences Investors has become the go-to destination for investors seeking a reliable and experienced mutual fund company that can help them achieve their financial aspirations.
Holdings
From latest SEC N-PORT filing · US-listed stocks only
| # | Security Name | CUSIP | Asset Type | Weight % | Value ($M) | Quantity |
|---|---|---|---|---|---|---|
| 1 | ABEO Abeona Therapeutics Inc Since 2026-05-10 | 00289Y206 | Equity (Common) |
0.58%
|
$3.25 | 616,413 |
| 2 | JBIO Jade Biosciences Inc Since 2026-05-10 | 008064206 | Equity (Common) |
0.77%
|
$4.28 | 277,555 |
| 3 | ALLO Allogene Therapeutics Inc Since 2026-05-10 | 019770106 | Equity (Common) |
0.51%
|
$2.86 | 2,086,332 |
| 4 | ALNY Alnylam Pharmaceuticals Inc Since 2026-05-10 | 02043Q107 | Equity (Common) |
2.06%
|
$11.42 | 28,726 |
| 5 | AMGN Amgen Inc Since 2026-05-10 | 031162100 | Equity (Common) |
3.99%
|
$22.15 | 67,677 |
| 6 | APGE Apogee Therapeutics Inc Since 2026-05-10 | 03770N101 | Equity (Common) |
0.49%
|
$2.73 | 36,103 |
| 7 | AQST Aquestive Therapeutics Inc Since 2026-05-10 | 03843E104 | Equity (Common) |
0.30%
|
$1.65 | 255,905 |
| 8 | ACLX Arcellx Inc Since 2026-05-10 | 03940C100 | Equity (Common) |
0.23%
|
$1.27 | 19,562 |
| 9 | RCUS Arcus Biosciences Inc Since 2026-05-10 | 03969F109 | Equity (Common) |
0.26%
|
$1.44 | 60,608 |
| 10 | ARQT Arcutis Biotherapeutics Inc Since 2026-05-10 | 03969K108 | Equity (Common) |
0.75%
|
$4.19 | 144,311 |
| 11 | ARWR Arrowhead Pharmaceuticals Inc Since 2026-05-10 | 04280A100 | Equity (Common) |
1.44%
|
$7.99 | 120,388 |
| 12 | AVTX Avalo Therapeutics Inc Since 2026-05-10 | 05338F306 | Equity (Common) |
0.31%
|
$1.73 | 95,426 |
| 13 | AXSM Axsome Therapeutics Inc Since 2026-05-10 | 05464T104 | Equity (Common) |
1.30%
|
$7.23 | 39,565 |
| 14 | BCRX BioCryst Pharmaceuticals Inc Since 2026-05-10 | 09058V103 | Equity (Common) |
0.26%
|
$1.47 | 187,803 |
| 15 | CRBU Caribou Biosciences Inc Since 2026-05-10 | 142038108 | Equity (Common) |
0.40%
|
$2.21 | 1,388,905 |
| 16 | CDXS Codexis Inc Since 2026-05-10 | 192005106 | Equity (Common) |
0.80%
|
$4.46 | 2,734,032 |
| 17 | CRBP Corbus Pharmaceuticals Holdings Inc Since 2026-05-10 | 21833P301 | Equity (Common) |
0.80%
|
$4.43 | 543,719 |
| 18 | CRNX Crinetics Pharmaceuticals Inc Since 2026-05-10 | 22663K107 | Equity (Common) |
2.22%
|
$12.34 | 265,141 |
| 19 | DNLI Denali Therapeutics Inc Since 2026-05-10 | 24823R105 | Equity (Common) |
2.15%
|
$11.92 | 721,733 |
| 20 | IRON Disc Medicine Inc Since 2026-05-10 | 254604101 | Equity (Common) |
0.88%
|
$4.86 | 61,234 |
| 21 | DYN Dyne Therapeutics Inc Since 2026-05-10 | 26818M108 | Equity (Common) |
2.32%
|
$12.90 | 659,460 |
| 22 | EWTX Edgewise Therapeutics Inc Since 2026-05-10 | 28036F105 | Equity (Common) |
1.58%
|
$8.75 | 352,615 |
| 23 | EQ Equillium Inc Since 2026-05-10 | 29446K106 | Equity (Common) |
0.66%
|
$3.67 | 2,366,688 |
| 24 | EVMN Evommune Inc Since 2026-05-10 | 30054Y107 | Equity (Common) |
0.54%
|
$2.99 | 174,581 |
| 25 | EYPT EyePoint Inc Since 2026-05-10 | 30233G209 | Equity (Common) |
1.77%
|
$9.82 | 537,447 |
| 26 | FULC Fulcrum Therapeutics Inc Since 2026-05-10 | 359616109 | Equity (Common) |
2.55%
|
$14.18 | 1,254,027 |
| 27 | GILD Gilead Sciences Inc Since 2026-05-10 | 375558103 | Equity (Common) |
0.47%
|
$2.62 | 21,337 |
| 28 | GRAL GRAIL Inc Since 2026-05-10 | 384747101 | Equity (Common) |
0.64%
|
$3.56 | 41,603 |
| 29 | GH Guardant Health Inc Since 2026-05-10 | 40131M109 | Equity (Common) |
0.65%
|
$3.60 | 35,219 |
| 30 | IDYA Ideaya Biosciences Inc Since 2026-05-10 | 45166A102 | Equity (Common) |
1.34%
|
$7.44 | 215,279 |
| 31 | IMVT Immunovant Inc Since 2026-05-10 | 45258J102 | Equity (Common) |
2.02%
|
$11.22 | 441,498 |
| 32 | IMUX Immunic Inc Since 2026-05-10 | 4525EP101 | Equity (Common) |
0.29%
|
$1.62 | 3,028,916 |
| 33 | IONS Ionis Pharmaceuticals Inc Since 2026-05-10 | 462222100 | Equity (Common) |
0.41%
|
$2.29 | 28,926 |
| 34 | IOVA Iovance Biotherapeutics Inc Since 2026-05-10 | 462260100 | Equity (Common) |
0.37%
|
$2.07 | 759,522 |
| 35 | KRYS Krystal Biotech Inc Since 2026-05-10 | 501147102 | Equity (Common) |
0.63%
|
$3.48 | 14,121 |
| 36 | LENZ LENZ Therapeutics Inc Since 2026-05-10 | 52635N103 | Equity (Common) |
0.45%
|
$2.49 | 155,610 |
| 37 | NBIX Neurocrine Biosciences Inc Since 2026-05-10 | 64125C109 | Equity (Common) |
0.51%
|
$2.85 | 20,093 |
| 38 | NUVL Nuvalent Inc Since 2026-05-10 | 670703107 | Equity (Common) |
1.26%
|
$6.97 | 69,310 |
| 39 | ORKA Oruka Therapeutics Inc Since 2026-05-10 | 687604108 | Equity (Common) |
0.41%
|
$2.29 | 75,680 |
| 40 | PSNL Personalis Inc Since 2026-05-10 | 71535D106 | Equity (Common) |
1.94%
|
$10.78 | 1,354,053 |
| 41 | PRAX Praxis Precision Medicines Inc Since 2026-05-10 | 74006W207 | Equity (Common) |
0.95%
|
$5.25 | 17,814 |
| 42 | DTIL Precision BioSciences Inc Since 2026-05-10 | 74019P207 | Equity (Common) |
0.78%
|
$4.34 | 1,043,752 |
| 43 | REGN Regeneron Pharmaceuticals Inc Since 2026-05-10 | 75886F107 | Equity (Common) |
3.80%
|
$21.09 | 27,329 |
| 44 | RVMD Revolution Medicines Inc Since 2026-05-10 | 76155X100 | Equity (Common) |
0.53%
|
$2.92 | 36,678 |
| 45 | SRPT Sarepta Therapeutics Inc Since 2026-05-10 | 803607100 | Equity (Common) |
1.61%
|
$8.96 | 416,313 |
| 46 | STTK Shattuck Labs Inc Since 2026-05-10 | 82024L103 | Equity (Common) |
0.35%
|
$1.94 | 531,177 |
| 47 | SPRY ARS Pharmaceuticals Inc Since 2026-05-10 | 82835W108 | Equity (Common) |
1.22%
|
$6.77 | 581,057 |
| 48 | SION Sionna Therapeutics Inc Since 2026-05-10 | 829401108 | Equity (Common) |
1.88%
|
$10.47 | 254,414 |
| 49 | SLNO Soleno Therapeutics Inc Since 2026-05-10 | 834203309 | Equity (Common) |
0.81%
|
$4.51 | 97,455 |
| 50 | SMMT Summit Therapeutics Inc Since 2026-05-10 | 86627T108 | Equity (Common) |
1.02%
|
$5.68 | 324,733 |
| 51 | SNDX Syndax Pharmaceuticals Inc Since 2026-05-10 | 87164F105 | Equity (Common) |
1.41%
|
$7.83 | 372,792 |
| 52 | TSHA Taysha Gene Therapies Inc Since 2026-05-10 | 877619106 | Equity (Common) |
1.01%
|
$5.62 | 1,021,063 |
| 53 | TECX Tectonic Therapeutic Inc Since 2026-05-10 | 878972108 | Equity (Common) |
1.39%
|
$7.74 | 370,884 |
| 54 | TEM Tempus AI Inc Since 2026-05-10 | 88023B103 | Equity (Common) |
1.00%
|
$5.58 | 94,511 |
| 55 | TVTX Travere Therapeutics Inc Since 2026-05-10 | 89422G107 | Equity (Common) |
1.42%
|
$7.87 | 205,865 |
| 56 | TCRX TScan Therapeutics Inc Since 2026-05-10 | 89854M101 | Equity (Common) |
0.17%
|
$0.94 | 941,693 |
| 57 | RARE Ultragenyx Pharmaceutical Inc Since 2026-05-10 | 90400D108 | Equity (Common) |
2.06%
|
$11.43 | 497,078 |
| 58 | PCVX Vaxcyte Inc Since 2026-05-10 | 92243G108 | Equity (Common) |
2.62%
|
$14.54 | 315,222 |
| 59 | VIR Vir Biotechnology Inc Since 2026-05-10 | 92764N102 | Equity (Common) |
0.56%
|
$3.08 | 511,363 |
| 60 | IMUX IMMUNIC INC. Since 2026-05-10 | — | Derivative | — | — | 2,311,826 |
| 61 | IMUX IMMUNIC INC. Since 2026-05-10 | — | Derivative |
0.22%
|
$1.23 | 2,311,826 |
| 62 | IMUX IMMUNIC INC. Since 2026-05-10 | — | Derivative |
0.08%
|
$0.46 | 2,311,826 |
| 63 | XENE Xenon Pharmaceuticals Inc Since 2026-05-10 | 98420N105 | Equity (Common) |
2.15%
|
$11.92 | 266,030 |
| 64 | DTIL PRECISION BIOSCIENCES Since 2026-05-10 | — | Derivative |
0.14%
|
$0.78 | 336,267 |
| 65 | BHVN Biohaven Ltd Since 2026-05-10 | — | Equity (Common) |
1.41%
|
$7.83 | 693,452 |
| 66 | JAZZ Jazz Pharmaceuticals PLC Since 2026-05-10 | — | Equity (Common) |
0.39%
|
$2.18 | 12,845 |
| 67 | OCS Oculis Holding AG Since 2026-05-10 | — | Equity (Common) |
0.91%
|
$5.07 | 253,740 |